# Multicentric Randomised Trial for Resectable Gastric Cancer

> **NCT02931890** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **The Netherlands Cancer Institute** · enrollment: 207 (estimated)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** Docetaxel
- **DRUG:** Oxaliplatin
- **DRUG:** Capecitabine
- **PROCEDURE:** gastrectomy
- **RADIATION:** radiotherapy of gastric cancer
- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT02931890
- **Lead sponsor:** The Netherlands Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-12-21
- **Primary completion:** 2025-04
- **Final completion:** 2029-03
- **Target enrollment:** 207 (ESTIMATED)
- **Last updated:** 2024-05-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02931890

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02931890, "Multicentric Randomised Trial for Resectable Gastric Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02931890. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*